Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
In a phase 3 trial, adults (≥60 years of age) received one 120-μg dose of RSVpreF vaccine (17,215) or placebo (17,069). Vaccine efficacy against RSV-associated lower respiratory tract illness was 67 to 86%.
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2023-04, Vol.388 (16), p.1465-1477 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1477 |
|---|---|
| container_issue | 16 |
| container_start_page | 1465 |
| container_title | The New England journal of medicine |
| container_volume | 388 |
| creator | Walsh, Edward E. Pérez Marc, Gonzalo Zareba, Agnieszka M. Falsey, Ann R. Jiang, Qin Patton, Michael Polack, Fernando P. Llapur, Conrado Doreski, Pablo A. Ilangovan, Kumar Rämet, Mika Fukushima, Yasushi Hussen, Nazreen Bont, Louis J. Cardona, Jose DeHaan, Elliot Castillo Villa, Giselle Ingilizova, Marinela Eiras, Daniel Mikati, Tarek Shah, Rupal N. Schneider, Katherine Cooper, David Koury, Kenneth Lino, Maria-Maddalena Anderson, Annaliesa S. Jansen, Kathrin U. Swanson, Kena A. Gurtman, Alejandra Gruber, William C. Schmoele-Thoma, Beate |
| description | In a phase 3 trial, adults (≥60 years of age) received one 120-μg dose of RSVpreF vaccine (17,215) or placebo (17,069). Vaccine efficacy against RSV-associated lower respiratory tract illness was 67 to 86%. |
| doi_str_mv | 10.1056/NEJMoa2213836 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2797147177</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2803496739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-f1e7e6e957d72394442b9dd41322df5ea8c1db01ec726329b4b56fcfc44df8ae3</originalsourceid><addsrcrecordid>eNp10M9LwzAUB_Agis7p0asERPBSza82zVHHphN14nTXkiYv0NGms2mF_fdWNgUF3-VdPnx574vQCSWXlMTJ1dP4_rHWjFGe8mQHDWjMeSQESXbRgBCWRkIqfoAOQ1iSfqhQ--iAS0JTkaQDNB07Vxht1lh7i-faQbvGtcMa3xQfugTf4pf5Aj834LpQ1B5P8EIbU3jAhcez0kKDr21XtuEI7TldBjje7iF6m4xfR3fRw-x2Orp-iAwnso0cBQkJqFhaybgSQrBcWSsoZ8y6GHRqqM0JBSNZwpnKRR4nzjgjhHWpBj5EF5vcVVO_dxDarCqCgbLUHuouZEwqSYWkUvb07A9d1l3j--sylhIuVCK56lW0UaapQ-gfzVZNUelmnVGSfXWc_eq496fb1C6vwP7o71J7cL4BVRUyD8vqn6BP8mKAHw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2803496739</pqid></control><display><type>article</type><title>Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Walsh, Edward E. ; Pérez Marc, Gonzalo ; Zareba, Agnieszka M. ; Falsey, Ann R. ; Jiang, Qin ; Patton, Michael ; Polack, Fernando P. ; Llapur, Conrado ; Doreski, Pablo A. ; Ilangovan, Kumar ; Rämet, Mika ; Fukushima, Yasushi ; Hussen, Nazreen ; Bont, Louis J. ; Cardona, Jose ; DeHaan, Elliot ; Castillo Villa, Giselle ; Ingilizova, Marinela ; Eiras, Daniel ; Mikati, Tarek ; Shah, Rupal N. ; Schneider, Katherine ; Cooper, David ; Koury, Kenneth ; Lino, Maria-Maddalena ; Anderson, Annaliesa S. ; Jansen, Kathrin U. ; Swanson, Kena A. ; Gurtman, Alejandra ; Gruber, William C. ; Schmoele-Thoma, Beate</creator><creatorcontrib>Walsh, Edward E. ; Pérez Marc, Gonzalo ; Zareba, Agnieszka M. ; Falsey, Ann R. ; Jiang, Qin ; Patton, Michael ; Polack, Fernando P. ; Llapur, Conrado ; Doreski, Pablo A. ; Ilangovan, Kumar ; Rämet, Mika ; Fukushima, Yasushi ; Hussen, Nazreen ; Bont, Louis J. ; Cardona, Jose ; DeHaan, Elliot ; Castillo Villa, Giselle ; Ingilizova, Marinela ; Eiras, Daniel ; Mikati, Tarek ; Shah, Rupal N. ; Schneider, Katherine ; Cooper, David ; Koury, Kenneth ; Lino, Maria-Maddalena ; Anderson, Annaliesa S. ; Jansen, Kathrin U. ; Swanson, Kena A. ; Gurtman, Alejandra ; Gruber, William C. ; Schmoele-Thoma, Beate ; RENOIR Clinical Trial Group</creatorcontrib><description>In a phase 3 trial, adults (≥60 years of age) received one 120-μg dose of RSVpreF vaccine (17,215) or placebo (17,069). Vaccine efficacy against RSV-associated lower respiratory tract illness was 67 to 86%.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2213836</identifier><identifier>PMID: 37018468</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adverse events ; Aged ; Aging ; Aging General ; Antibodies, Viral ; Antigens ; Chronic illnesses ; Coronaviruses ; COVID-19 ; Double-Blind Method ; F protein ; Geriatrics ; Global Health ; Hepatitis ; Humans ; Immunization ; Infections ; Infectious Disease ; Infectious Disease General ; Influenza ; Injection ; Injections, Intramuscular ; Middle Aged ; Older people ; Placebos ; Respiratory diseases ; Respiratory syncytial virus ; Respiratory Syncytial Virus Infections - diagnosis ; Respiratory Syncytial Virus Infections - epidemiology ; Respiratory Syncytial Virus Infections - prevention & control ; Respiratory Syncytial Virus Vaccines - administration & dosage ; Respiratory Syncytial Virus Vaccines - adverse effects ; Respiratory Syncytial Virus Vaccines - therapeutic use ; Respiratory tract ; Respiratory Tract Infections - diagnosis ; Respiratory Tract Infections - epidemiology ; Respiratory Tract Infections - prevention & control ; Safety ; Seasons ; Treatment Outcome ; Vaccine Efficacy ; Vaccines ; Vaccines, Combined - administration & dosage ; Vaccines, Combined - adverse effects ; Vaccines, Combined - therapeutic use ; Viral Infections</subject><ispartof>The New England journal of medicine, 2023-04, Vol.388 (16), p.1465-1477</ispartof><rights>Copyright © 2023 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2023 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c307t-f1e7e6e957d72394442b9dd41322df5ea8c1db01ec726329b4b56fcfc44df8ae3</cites><orcidid>0000-0002-6148-215X ; 0000-0002-3389-8414</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2213836$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa2213836$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37018468$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walsh, Edward E.</creatorcontrib><creatorcontrib>Pérez Marc, Gonzalo</creatorcontrib><creatorcontrib>Zareba, Agnieszka M.</creatorcontrib><creatorcontrib>Falsey, Ann R.</creatorcontrib><creatorcontrib>Jiang, Qin</creatorcontrib><creatorcontrib>Patton, Michael</creatorcontrib><creatorcontrib>Polack, Fernando P.</creatorcontrib><creatorcontrib>Llapur, Conrado</creatorcontrib><creatorcontrib>Doreski, Pablo A.</creatorcontrib><creatorcontrib>Ilangovan, Kumar</creatorcontrib><creatorcontrib>Rämet, Mika</creatorcontrib><creatorcontrib>Fukushima, Yasushi</creatorcontrib><creatorcontrib>Hussen, Nazreen</creatorcontrib><creatorcontrib>Bont, Louis J.</creatorcontrib><creatorcontrib>Cardona, Jose</creatorcontrib><creatorcontrib>DeHaan, Elliot</creatorcontrib><creatorcontrib>Castillo Villa, Giselle</creatorcontrib><creatorcontrib>Ingilizova, Marinela</creatorcontrib><creatorcontrib>Eiras, Daniel</creatorcontrib><creatorcontrib>Mikati, Tarek</creatorcontrib><creatorcontrib>Shah, Rupal N.</creatorcontrib><creatorcontrib>Schneider, Katherine</creatorcontrib><creatorcontrib>Cooper, David</creatorcontrib><creatorcontrib>Koury, Kenneth</creatorcontrib><creatorcontrib>Lino, Maria-Maddalena</creatorcontrib><creatorcontrib>Anderson, Annaliesa S.</creatorcontrib><creatorcontrib>Jansen, Kathrin U.</creatorcontrib><creatorcontrib>Swanson, Kena A.</creatorcontrib><creatorcontrib>Gurtman, Alejandra</creatorcontrib><creatorcontrib>Gruber, William C.</creatorcontrib><creatorcontrib>Schmoele-Thoma, Beate</creatorcontrib><creatorcontrib>RENOIR Clinical Trial Group</creatorcontrib><title>Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In a phase 3 trial, adults (≥60 years of age) received one 120-μg dose of RSVpreF vaccine (17,215) or placebo (17,069). Vaccine efficacy against RSV-associated lower respiratory tract illness was 67 to 86%.</description><subject>Adverse events</subject><subject>Aged</subject><subject>Aging</subject><subject>Aging General</subject><subject>Antibodies, Viral</subject><subject>Antigens</subject><subject>Chronic illnesses</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Double-Blind Method</subject><subject>F protein</subject><subject>Geriatrics</subject><subject>Global Health</subject><subject>Hepatitis</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infections</subject><subject>Infectious Disease</subject><subject>Infectious Disease General</subject><subject>Influenza</subject><subject>Injection</subject><subject>Injections, Intramuscular</subject><subject>Middle Aged</subject><subject>Older people</subject><subject>Placebos</subject><subject>Respiratory diseases</subject><subject>Respiratory syncytial virus</subject><subject>Respiratory Syncytial Virus Infections - diagnosis</subject><subject>Respiratory Syncytial Virus Infections - epidemiology</subject><subject>Respiratory Syncytial Virus Infections - prevention & control</subject><subject>Respiratory Syncytial Virus Vaccines - administration & dosage</subject><subject>Respiratory Syncytial Virus Vaccines - adverse effects</subject><subject>Respiratory Syncytial Virus Vaccines - therapeutic use</subject><subject>Respiratory tract</subject><subject>Respiratory Tract Infections - diagnosis</subject><subject>Respiratory Tract Infections - epidemiology</subject><subject>Respiratory Tract Infections - prevention & control</subject><subject>Safety</subject><subject>Seasons</subject><subject>Treatment Outcome</subject><subject>Vaccine Efficacy</subject><subject>Vaccines</subject><subject>Vaccines, Combined - administration & dosage</subject><subject>Vaccines, Combined - adverse effects</subject><subject>Vaccines, Combined - therapeutic use</subject><subject>Viral Infections</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10M9LwzAUB_Agis7p0asERPBSza82zVHHphN14nTXkiYv0NGms2mF_fdWNgUF3-VdPnx574vQCSWXlMTJ1dP4_rHWjFGe8mQHDWjMeSQESXbRgBCWRkIqfoAOQ1iSfqhQ--iAS0JTkaQDNB07Vxht1lh7i-faQbvGtcMa3xQfugTf4pf5Aj834LpQ1B5P8EIbU3jAhcez0kKDr21XtuEI7TldBjje7iF6m4xfR3fRw-x2Orp-iAwnso0cBQkJqFhaybgSQrBcWSsoZ8y6GHRqqM0JBSNZwpnKRR4nzjgjhHWpBj5EF5vcVVO_dxDarCqCgbLUHuouZEwqSYWkUvb07A9d1l3j--sylhIuVCK56lW0UaapQ-gfzVZNUelmnVGSfXWc_eq496fb1C6vwP7o71J7cL4BVRUyD8vqn6BP8mKAHw</recordid><startdate>20230420</startdate><enddate>20230420</enddate><creator>Walsh, Edward E.</creator><creator>Pérez Marc, Gonzalo</creator><creator>Zareba, Agnieszka M.</creator><creator>Falsey, Ann R.</creator><creator>Jiang, Qin</creator><creator>Patton, Michael</creator><creator>Polack, Fernando P.</creator><creator>Llapur, Conrado</creator><creator>Doreski, Pablo A.</creator><creator>Ilangovan, Kumar</creator><creator>Rämet, Mika</creator><creator>Fukushima, Yasushi</creator><creator>Hussen, Nazreen</creator><creator>Bont, Louis J.</creator><creator>Cardona, Jose</creator><creator>DeHaan, Elliot</creator><creator>Castillo Villa, Giselle</creator><creator>Ingilizova, Marinela</creator><creator>Eiras, Daniel</creator><creator>Mikati, Tarek</creator><creator>Shah, Rupal N.</creator><creator>Schneider, Katherine</creator><creator>Cooper, David</creator><creator>Koury, Kenneth</creator><creator>Lino, Maria-Maddalena</creator><creator>Anderson, Annaliesa S.</creator><creator>Jansen, Kathrin U.</creator><creator>Swanson, Kena A.</creator><creator>Gurtman, Alejandra</creator><creator>Gruber, William C.</creator><creator>Schmoele-Thoma, Beate</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6148-215X</orcidid><orcidid>https://orcid.org/0000-0002-3389-8414</orcidid></search><sort><creationdate>20230420</creationdate><title>Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults</title><author>Walsh, Edward E. ; Pérez Marc, Gonzalo ; Zareba, Agnieszka M. ; Falsey, Ann R. ; Jiang, Qin ; Patton, Michael ; Polack, Fernando P. ; Llapur, Conrado ; Doreski, Pablo A. ; Ilangovan, Kumar ; Rämet, Mika ; Fukushima, Yasushi ; Hussen, Nazreen ; Bont, Louis J. ; Cardona, Jose ; DeHaan, Elliot ; Castillo Villa, Giselle ; Ingilizova, Marinela ; Eiras, Daniel ; Mikati, Tarek ; Shah, Rupal N. ; Schneider, Katherine ; Cooper, David ; Koury, Kenneth ; Lino, Maria-Maddalena ; Anderson, Annaliesa S. ; Jansen, Kathrin U. ; Swanson, Kena A. ; Gurtman, Alejandra ; Gruber, William C. ; Schmoele-Thoma, Beate</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-f1e7e6e957d72394442b9dd41322df5ea8c1db01ec726329b4b56fcfc44df8ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adverse events</topic><topic>Aged</topic><topic>Aging</topic><topic>Aging General</topic><topic>Antibodies, Viral</topic><topic>Antigens</topic><topic>Chronic illnesses</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Double-Blind Method</topic><topic>F protein</topic><topic>Geriatrics</topic><topic>Global Health</topic><topic>Hepatitis</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infections</topic><topic>Infectious Disease</topic><topic>Infectious Disease General</topic><topic>Influenza</topic><topic>Injection</topic><topic>Injections, Intramuscular</topic><topic>Middle Aged</topic><topic>Older people</topic><topic>Placebos</topic><topic>Respiratory diseases</topic><topic>Respiratory syncytial virus</topic><topic>Respiratory Syncytial Virus Infections - diagnosis</topic><topic>Respiratory Syncytial Virus Infections - epidemiology</topic><topic>Respiratory Syncytial Virus Infections - prevention & control</topic><topic>Respiratory Syncytial Virus Vaccines - administration & dosage</topic><topic>Respiratory Syncytial Virus Vaccines - adverse effects</topic><topic>Respiratory Syncytial Virus Vaccines - therapeutic use</topic><topic>Respiratory tract</topic><topic>Respiratory Tract Infections - diagnosis</topic><topic>Respiratory Tract Infections - epidemiology</topic><topic>Respiratory Tract Infections - prevention & control</topic><topic>Safety</topic><topic>Seasons</topic><topic>Treatment Outcome</topic><topic>Vaccine Efficacy</topic><topic>Vaccines</topic><topic>Vaccines, Combined - administration & dosage</topic><topic>Vaccines, Combined - adverse effects</topic><topic>Vaccines, Combined - therapeutic use</topic><topic>Viral Infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walsh, Edward E.</creatorcontrib><creatorcontrib>Pérez Marc, Gonzalo</creatorcontrib><creatorcontrib>Zareba, Agnieszka M.</creatorcontrib><creatorcontrib>Falsey, Ann R.</creatorcontrib><creatorcontrib>Jiang, Qin</creatorcontrib><creatorcontrib>Patton, Michael</creatorcontrib><creatorcontrib>Polack, Fernando P.</creatorcontrib><creatorcontrib>Llapur, Conrado</creatorcontrib><creatorcontrib>Doreski, Pablo A.</creatorcontrib><creatorcontrib>Ilangovan, Kumar</creatorcontrib><creatorcontrib>Rämet, Mika</creatorcontrib><creatorcontrib>Fukushima, Yasushi</creatorcontrib><creatorcontrib>Hussen, Nazreen</creatorcontrib><creatorcontrib>Bont, Louis J.</creatorcontrib><creatorcontrib>Cardona, Jose</creatorcontrib><creatorcontrib>DeHaan, Elliot</creatorcontrib><creatorcontrib>Castillo Villa, Giselle</creatorcontrib><creatorcontrib>Ingilizova, Marinela</creatorcontrib><creatorcontrib>Eiras, Daniel</creatorcontrib><creatorcontrib>Mikati, Tarek</creatorcontrib><creatorcontrib>Shah, Rupal N.</creatorcontrib><creatorcontrib>Schneider, Katherine</creatorcontrib><creatorcontrib>Cooper, David</creatorcontrib><creatorcontrib>Koury, Kenneth</creatorcontrib><creatorcontrib>Lino, Maria-Maddalena</creatorcontrib><creatorcontrib>Anderson, Annaliesa S.</creatorcontrib><creatorcontrib>Jansen, Kathrin U.</creatorcontrib><creatorcontrib>Swanson, Kena A.</creatorcontrib><creatorcontrib>Gurtman, Alejandra</creatorcontrib><creatorcontrib>Gruber, William C.</creatorcontrib><creatorcontrib>Schmoele-Thoma, Beate</creatorcontrib><creatorcontrib>RENOIR Clinical Trial Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walsh, Edward E.</au><au>Pérez Marc, Gonzalo</au><au>Zareba, Agnieszka M.</au><au>Falsey, Ann R.</au><au>Jiang, Qin</au><au>Patton, Michael</au><au>Polack, Fernando P.</au><au>Llapur, Conrado</au><au>Doreski, Pablo A.</au><au>Ilangovan, Kumar</au><au>Rämet, Mika</au><au>Fukushima, Yasushi</au><au>Hussen, Nazreen</au><au>Bont, Louis J.</au><au>Cardona, Jose</au><au>DeHaan, Elliot</au><au>Castillo Villa, Giselle</au><au>Ingilizova, Marinela</au><au>Eiras, Daniel</au><au>Mikati, Tarek</au><au>Shah, Rupal N.</au><au>Schneider, Katherine</au><au>Cooper, David</au><au>Koury, Kenneth</au><au>Lino, Maria-Maddalena</au><au>Anderson, Annaliesa S.</au><au>Jansen, Kathrin U.</au><au>Swanson, Kena A.</au><au>Gurtman, Alejandra</au><au>Gruber, William C.</au><au>Schmoele-Thoma, Beate</au><aucorp>RENOIR Clinical Trial Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2023-04-20</date><risdate>2023</risdate><volume>388</volume><issue>16</issue><spage>1465</spage><epage>1477</epage><pages>1465-1477</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>In a phase 3 trial, adults (≥60 years of age) received one 120-μg dose of RSVpreF vaccine (17,215) or placebo (17,069). Vaccine efficacy against RSV-associated lower respiratory tract illness was 67 to 86%.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>37018468</pmid><doi>10.1056/NEJMoa2213836</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-6148-215X</orcidid><orcidid>https://orcid.org/0000-0002-3389-8414</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2023-04, Vol.388 (16), p.1465-1477 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2797147177 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Adverse events Aged Aging Aging General Antibodies, Viral Antigens Chronic illnesses Coronaviruses COVID-19 Double-Blind Method F protein Geriatrics Global Health Hepatitis Humans Immunization Infections Infectious Disease Infectious Disease General Influenza Injection Injections, Intramuscular Middle Aged Older people Placebos Respiratory diseases Respiratory syncytial virus Respiratory Syncytial Virus Infections - diagnosis Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus Vaccines - administration & dosage Respiratory Syncytial Virus Vaccines - adverse effects Respiratory Syncytial Virus Vaccines - therapeutic use Respiratory tract Respiratory Tract Infections - diagnosis Respiratory Tract Infections - epidemiology Respiratory Tract Infections - prevention & control Safety Seasons Treatment Outcome Vaccine Efficacy Vaccines Vaccines, Combined - administration & dosage Vaccines, Combined - adverse effects Vaccines, Combined - therapeutic use Viral Infections |
| title | Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T15%3A48%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20a%20Bivalent%20RSV%20Prefusion%20F%20Vaccine%20in%20Older%20Adults&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Walsh,%20Edward%20E.&rft.aucorp=RENOIR%20Clinical%20Trial%20Group&rft.date=2023-04-20&rft.volume=388&rft.issue=16&rft.spage=1465&rft.epage=1477&rft.pages=1465-1477&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2213836&rft_dat=%3Cproquest_cross%3E2803496739%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2803496739&rft_id=info:pmid/37018468&rfr_iscdi=true |